Study S000596
Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase
Registration
Registered primary outcomes
- Mild cognitive impairment (MCI) remission rate [The core study spans from baseline to 48 weeks]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0018433 | Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase. Yu C, BMJ open | 2025 | Protocol | PMID 40840993DOI | cites ClinicalTrials.gov:NCT05313529; registry reference DERIVED:40840993 |
| R0022403 | Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Cheng H, Diabetes care | 2022 | Randomized trial | PMID 35263425DOI | registry reference RESULT:35263425 |
| R0011068 | Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Zhang Z, Diabetes care | 2019 | Other | PMID 31221697DOI | registry reference RESULT:31221697 |